Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation

BACKGROUND: Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. In clinical trials, the most common adverse events observed were nasopharyngitis, upper respiratory tract infections, and zoster. JAKs are...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Arthritis Res Ther
Egile Nagusiak: Hawerkamp, Heike C., Domdey, Alina, Radau, Lisa, Sewerin, Philipp, Oláh, Péter, Homey, Bernhard, Meller, Stephan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2021
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138978/
https://ncbi.nlm.nih.gov/pubmed/34020693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-021-02509-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak